Lucid Diagnostics prices $15M public offering of 12.5M shares at $1.20 per share

Lucid Diagnostics Inc.

Gross proceeds ~$15M from 12.5M shares at $1.20; underwriters have 45-day option for 1.875M additional shares.
Closing expected April 11, 2025; net proceeds for working capital and general corporate purposes.
Canaccord Genuity sole bookrunner, Maxim Group co-manager; offered under shelf registration effective Dec 2022.
Offering significantly dilutes existing shareholders; exact dilution depends on option exercise.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.